{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:56:45Z","timestamp":1761505005310,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.yebeh.2022.108704","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:32:37Z","timestamp":1651210357000},"page":"108704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PA","title":["Reply to comments on \u201cA scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development\u201d"],"prefix":"10.1016","volume":"131","author":[{"given":"Debopam","family":"Samanta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.108704_b0005","doi-asserted-by":"crossref","first-page":"108577","DOI":"10.1016\/j.yebeh.2022.108577","article-title":"A scoping review on cannabidiol therapy in tuberous sclerosis: current evidence and perspectives for future development","volume":"128","author":"Samanta","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108704_b0010","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-On cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2022.108704_b0015","first-page":"24","article-title":"Cannabidiol: a review of clinical efficacy and safety in epilepsy","volume":"96","author":"Samanta","year":"2019","journal-title":"PediatrNeurol"},{"key":"10.1016\/j.yebeh.2022.108704_b0020","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/epi.16542","article-title":"Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108704_b0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ane.13305","article-title":"Cannabidiol efficacy independent of clobazam: meta-analysis of four randomized controlled trials","volume":"142","author":"Devinsky","year":"2020","journal-title":"Acta Neurol Scand"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022001536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022001536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:47:10Z","timestamp":1761504430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022001536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":5,"alternative-id":["S1525505022001536"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108704","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to comments on \u201cA scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development\u201d","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108704"}}